Evidence map›Paper›PMID 35722183›Full record

Observational studyUpsala journal of medical sciences2022

Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study.

Maria K Svensson, Francesc Sorio Vilela, Margrét Leósdóttir, Jonas Banefelt, Maria Lindh, Alexander Rieem Dun, Anna Norhammar, Guillermo Villa

Open access · diamondFull text readObservational Study
In one paragraph

Observational study in Upsala journal of medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Maria K SvenssonDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Francesc Sorio VilelaAmgen (Europe) GmbH, Suurstoffi 22, Rotkreuz, Switzerland.
Margrét LeósdóttirSkåne University Hospital and Department of Clinical Sciences, Lund University, Malmö, Sweden.
Jonas BanefeltQuantify Research, Hantverkargatan 8, Stockholm, Sweden.
Maria LindhQuantify Research, Hantverkargatan 8, Stockholm, Sweden.
Alexander Rieem DunQuantify Research, Hantverkargatan 8, Stockholm, Sweden.
Anna NorhammarKarolinska Institute, Solnavägen 1, Solna, Sweden.
Guillermo VillaAmgen (Europe) GmbH, Suurstoffi 22, Rotkreuz, Switzerland.
Quantify Research (Sweden) · SEAmgen (Switzerland) · CHKarolinska Institutet · SELund University · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Oral lipid-lowering treatment (LLT) is the standard of care for patients with cardiovascular disease (CVD). However, insufficient treatment intensity and poor adherence can lead to suboptimal treatment benefit, rendering patients at increased risk of CVD. Aims: The objective of this study was to evaluate trends in LLT intensity and adherence in Sweden over time, and their association with major adverse cardiovascular events (MACE) after recent myocardial infarction (MI), and also to assess the impact of transition from secondary to primary care on intensity and adherence. Methods and results: This retrospective observational cohort study used data from Swedish nationwide patient registers and included patients on LLT after an MI in the years 2010-2016 ( Conclusion: The proportion of post-MI patients with high LLT intensity and adherence has increased in recent years, with little change after transfer from specialist to primary care. The combination of LLT intensity and adherence is important for preventing future cardiovascular events.

Indexed as

Cardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsMyocardial InfarctionAgedFemaleHumansLipidsMaleProportional Hazards ModelsRetrospective StudiesSwedenHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsAdherenceezetimibelipid-lowering therapymajor adverse cardiovascular eventsmyocardial infarctionstatinstreatment intensity

Identifiers

PMID35722183
PMCPMC9171571
OpenAlexW4225371845

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.